These 3 Stocks Are Top Picks for 2022, Say Analysts

These 3 Stocks Are Top Picks for 2022, Say Analysts

TipRanks

Inovio: Making Progress in the Cervical HSIL Program

Inovio (INO) made a big splash last year with its Covid-19 DNA vaccine candidate INO-4800. Development, however, has been slow, and the vaccine is still a while away from entering the market, should it ever get that far. In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le

Post a Comment